Drug Information

Drug (ID: DG01682) and It's Reported Resistant Information

• Name: Letrozole/Ribociclib
• Synonyms: Letrozole/Ribociclib
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Breast cancer [ICD-11: 2C60]; [1]

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Breast cancer [ICD-11: 2C60]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Retinoblastoma-associated protein (RB1) [1]

• Resistant Disease: HER2 negative breast cancer [ICD-11: 2C60.11]
• Molecule Alteration: Missense mutation; p.H483Y (c.1447C>T)
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Blood sample; N.A.

References

• Ref 1: Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancerAnn Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784.